Psychosis and Type 2 Diabetes Study (PODS)
NCT05496907 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2022-12-15
Summary
People with severe mental illness (SMI), defined as psychotic and bipolar disorders, die 17-20 years earlier than the general population, the most common cause of death being cardiovascular diseases (CVD). The major contributor to CVD mortality in SMI is the increased prevalence of type 2 diabetes (T2D) compared to the general population. T2D is a paradigm of a single condition that progresses to multiple conditions. T2D requires annual reviews of 9 diabetes care processes and for patients to adopt multiple self-care tasks to prevent diabetes complications. The 9 diabetes care processes outlined by the NICE guidelines include: 3-6 monthly blood glucose measurement (HbA1c) with targets; blood pressure measurements and targets; annual blood cholesterol measurement; kidney function testing with urinary albumin; kidney function testing with serum creatinine; weight check; smoking status; diabetes annual eye screening; and annual foot examination.
Previous research has focused on upskilling mental health professionals or link workers in diabetes care, however, a primary care led focus to support individuals with T2D and SMI has not been investigated. This is an interventional study in Lambeth south London testing a new model of care for people with SMI and T2D that is led by the community DSN in collaboration with the PN and mental health team within the Hills Brook and Dales Primary Care Network (PCN). StockWELL PCN participants will act as controls. Participants will complete 7 validated questionnaires, a physical examination including a blood test and urine sample and a brief interview either face to face in their GP surgery. The intervention group will be invited to a clinic run by a DSN. Baseline measures will be repeated after 6 months in both groups. An exit interview will be conducted to determine participants thoughts on the intervention. This project has been funded by the Burdett Trust for Nursing.
Conditions
- Type 2 Diabetes
- Severe Mental Disorder
Interventions
- BEHAVIORAL
-
Diabetes specialist nurse-led collaborative care intervention
10 sessions with a diabetes nurse to help improve physical and mental health outcomes
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Kirsty Graham · King's College London University
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-22
- Primary Completion
- 2022-08-05
- Completion
- 2023-12-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
NCT00344500 ·Status: COMPLETED ·Phase: NA
-
Diabetes Prevention Program in Schizophrenia [DPPS]
NCT00182494 ·Status: UNKNOWN ·Phase: PHASE4
-
Pharmacoepigenetics of Bipolar Disorder Treatment
NCT02374996 ·Status: COMPLETED
-
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
NCT00790517 ·Status: COMPLETED ·Phase: PHASE2
-
Pioglitazone in Patients With Mood Disorders
NCT01559857 ·Status: COMPLETED ·Phase: PHASE4
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
NCT01052714 ·Status: COMPLETED ·Phase: NA
-
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
NCT05333003 ·Status: RECRUITING ·Phase: NA
-
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
NCT02029989 ·Status: COMPLETED ·Phase: NA
-
Antipsychotics and Risk of Hyperglycemic Emergencies
NCT02582736 ·Status: COMPLETED
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health
NCT05492305 ·Status: UNKNOWN
-
Weight Management Program for Patients With First Episode Psychosis
NCT05207982 ·Status: COMPLETED ·Phase: PHASE1
-
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT05744479 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Antipsychotics on Brain Insulin Action in Females
NCT06251635 ·Status: RECRUITING ·Phase: NA
-
Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups
NCT07212075 ·Status: RECRUITING
-
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
NCT02515773 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
NCT06331286 ·Status: UNKNOWN ·Phase: NA
-
Determining Metabolic Effects of Valproate and Antipsychotic Therapy
NCT00167934 ·Status: COMPLETED ·Phase: NA
-
Investigation Of How PD 0332334 And Metformin Are Eliminated From The Body When They Are Administered At The Same Time
NCT00809536 ·Status: TERMINATED ·Phase: PHASE1
-
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
NCT05748990 ·Status: RECRUITING ·Phase: NA
-
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
NCT00552500 ·Status: COMPLETED ·Phase: NA
-
Alleviating the Metabolic Side Effects of Antipsychotic Medications
NCT01567124 ·Status: WITHDRAWN ·Phase: PHASE4
-
Antipsychotics and Blood Vessel Function
NCT00585273 ·Status: COMPLETED
-
DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics
NCT00752960 ·Status: UNKNOWN
-
App and Body Fat Scale in the Management of Overweight Patients
NCT05866107 ·Status: RECRUITING ·Phase: NA